Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology

Ashwin Muraleetharan, Yuyang Wang, Matthew C. Rowe, Ashleigh Gould, Karen J. Gregory and Shane D. Hellyer
Molecular Pharmacology June 2023, 103 (6) 325-338; DOI: https://doi.org/10.1124/molpharm.122.000664
Ashwin Muraleetharan
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuyang Wang
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew C. Rowe
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashleigh Gould
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen J. Gregory
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane D. Hellyer
Drug Discovery Biology (A.M., Y.W., M.C.R., A.G., K.J.G., S.D.H.) and ARC Centre for Cryo-Electron Microscopy of Membrane Proteins (K.J.G.), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug discovery paradigms have not included rigorous pharmacological analysis. In the present study, we hypothesized that existing mGlu1 allosteric modulators possess unappreciated probe-dependent or biased pharmacology. Using human embryonic kidney 293 (HEK293A) cells stably expressing human mGlu1, we screened mGlu1 PAMs and NAMs from divergent chemical scaffolds for modulation of different mGlu1 orthosteric agonists in intracellular calcium (iCa2+) mobilization and inositol monophosphate (IP1) accumulation assays. Operational models of agonism and allosterism were used to derive estimates for important pharmacological parameters such as affinity, efficacy, and cooperativity. Modulation of glutamate and quisqualate-mediated iCa2+ mobilization revealed probe dependence at the level of affinity and cooperativity for both mGlu1 PAMs and NAMs. We also identified the previously described mGlu5 selective NAM PF-06462894 as an mGlu1 NAM with a different pharmacological profile from other NAMs. Differential profiles were also observed when comparing ligand pharmacology between iCa2+ mobilization and IP1 accumulation. The PAMs Ro67-4853 and CPPHA displayed apparent negative cooperativity for modulation of quisqualate affinity, and the NAMs CPCCOEt and PF-06462894 had a marked reduction in cooperativity with quisqualate in IP1 accumulation and upon extended incubation in iCa2+ mobilization assays. These data highlight the importance of rigorous assessment of mGlu1 modulator pharmacology to inform future drug discovery programs for mGlu1 allosteric modulators.

SIGNIFICANCE STATEMENT Metabotropic glutamate receptor subtype 1 (mGlu1) positive and negative allosteric modulators have therapeutic potential in multiple central nervous system disorders. We show that chemically distinct modulators display differential pharmacology with different orthosteric ligands and across divergent signaling pathways at human mGlu1. Such complexities in allosteric ligand pharmacology should be considered in future mGlu1 allosteric drug discovery programs.

Footnotes

    • Received December 15, 2022.
    • Accepted February 21, 2023.
  • This work was supported by a National Ataxia Foundation Early Career Investigator Award to S.D.H. Research on metabotropic glutamate receptor allosteric modulators within the Endocrine and Neuropharmacology laboratory was supported by an Australian Research Council Future Fellowship [FT170100392] and a National Health and Medical Research Council Australia Ideas grant [Grant 2002947] awarded to K.J.G.

  • No author has an actual or perceived conflict of interest with the contents of this article.

  • Select data from this work has previously been presented as:

  • Hellyer SD, Wang Y, Muraleetharan A, Rowe M, Gould A, and Gregory KJ (2022) Rigorous pharmacological characterization of metabotropic glutamate receptor 1. APSA/ASCEPT 2022 Joint Conference; 2022 Nov 29–Dec 2; Perth, WA, Australia; Australasian Pharmaceutical Science Association; and Hellyer SD, Wang Y, Muraleetharan A, and Gregory KJ (2022) Pharmacological characterization of mGlu1 in health and disease. Joint Florey and Monash Institute of Pharmaceutical Sciences Neurotherapeutics Symposium 2022; 2022 Oct 26; Melbourne, VIC, Australia.

  • dx.doi.org/10.1124/molpharm.120.000664.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

  • Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 103 (6)
Molecular Pharmacology
Vol. 103, Issue 6
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Allosteric Modulation of Metabotropic Glutamate Receptor 1

Ashwin Muraleetharan, Yuyang Wang, Matthew C. Rowe, Ashleigh Gould, Karen J. Gregory and Shane D. Hellyer
Molecular Pharmacology June 1, 2023, 103 (6) 325-338; DOI: https://doi.org/10.1124/molpharm.122.000664

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Allosteric Modulation of Metabotropic Glutamate Receptor 1

Ashwin Muraleetharan, Yuyang Wang, Matthew C. Rowe, Ashleigh Gould, Karen J. Gregory and Shane D. Hellyer
Molecular Pharmacology June 1, 2023, 103 (6) 325-338; DOI: https://doi.org/10.1124/molpharm.122.000664
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Data Availability
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Hexahydroquinoline derivatives activate ADGRG1/GPR56
  • Action of Org 34167 on HCN channels
  • The effects of echinocystic acid on Kv7 channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics